Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:23:08.564Z.
Calculation as of: 2026-10-06T16:23:08.564Z.
Quote observation: 2026-10-06T16:20:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
LB Pharmaceuticals Inc Common Stock
Market Cap
$999.27M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$989.25M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$991.85M
Price/FCF Ratio
N/A
TTM Avg
31.06
3Y Avg
31.06
5Y Avg
31.06
Market Cap
$1.00B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$983.38M
Price/FCF Ratio
5.48
TTM Avg
7.51
3Y Avg
7.85
5Y Avg
14.47
Market Cap
$1.02B
Price/FCF Ratio
31.97
TTM Avg
34.03
3Y Avg
34.03
5Y Avg
34.03
Market Cap
$1.03B
Price/FCF Ratio
N/A
TTM Avg
49.76
3Y Avg
32.52
5Y Avg
33.89
Market Cap
$1.04B
Price/FCF Ratio
N/A
TTM Avg
56.73
3Y Avg
40.99
5Y Avg
56.97
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $999.27M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $989.25M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $991.85M | N/A | 31.06 | 31.06 | 31.06 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.00B | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $983.38M | 5.48 | 7.51 | 7.85 | 14.47 |
| Aktis Oncology, Inc. (AKTS)vs › | $986.83M | N/A | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 31.97 | 34.03 | 34.03 | 34.03 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | N/A | 49.76 | 32.52 | 33.89 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | N/A | 56.73 | 40.99 | 56.97 |
| Kura Oncology, Inc. (KURA)vs › | $951.66M | N/A | 6.84 | 6.83 | 6.83 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
